NCT07779551

Brief Summary

There is significant difference between bupivacaine and ropivacaine in terms of postoperative pain assessment in patients undergoing total thyroidectomy with bilateral superficial cervical plexus block.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
94

participants targeted

Target at P50-P75 for not_applicable postoperative-pain

Timeline
3mo left

Started Jan 2026

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress71%
Jan 2026Dec 2026

Study Start

First participant enrolled

January 22, 2026

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

August 15, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 21, 2026

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Last Updated

August 21, 2026

Status Verified

August 1, 2026

Enrollment Period

10 months

First QC Date

August 15, 2026

Last Update Submit

August 19, 2026

Conditions

Postoperative Pain

Outcome Measures

Primary Outcomes (3)

  • Postoperative pain

    24 hours post surgery

  • time to the first request for analgesia

    24 hours postoperatively

  • Block-related complications

    immediately after the intervention/procedure

Study Arms (2)

Group 1 will receive 10ml of 0.25% bupivacaine on each side,

OTHER
Procedure: Group 1 will receive 10ml of 0.25% bupivacaine

Group 2 will receive 10ml of 0.25% ropivacaine on each side

OTHER
Procedure: Group 2 will receive 10ml of 0.25% ropivacaine on each side.

Interventions

Group 1 will receive 10ml of 0.25% bupivacainePROCEDURE

After placing the patients in a supine position with the neck slightly extended and rotated away from the side to be blocked,the procedure will be performed under sterile aseptic conditions.The sternocleidomastoid muscle will be identified,and a high-frequency (1O MHz) linear probe will be positioned transversely over the muscle,between the mastoid and clavicle. The cutaneous nerves of the cervical plexus,visible as round hypoechoic structures in the fascial plane beneath the muscle,will be targeted using a 22-gauge short block needle (5 cm) inserted in-plane with the transducer. Negative aspiration will be performed during injection to avoid inadvertent intravascular delivery. An emergency crash cart will remain available throughout the procedure.

Group 1 will receive 10ml of 0.25% bupivacaine on each side,
Group 2 will receive 10ml of 0.25% ropivacaine on each side.PROCEDURE

After placing the patients in a supine position with the neck slightly extended and rotated away from the side to be blocked,the procedure will be performed under sterile aseptic conditions.The sternocleidomastoid muscle will be identified,and a high-frequency (1O MHz) linear probe will be positioned transversely over the muscle,between the mastoid and clavicle. The cutaneous nerves of the cervical plexus,visible as round hypoechoic structures in the fascial plane beneath the muscle,will be targeted using a 22-gauge short block needle (5 cm) inserted in-plane with the transducer. Negative aspiration will be performed during injection to avoid inadvertent intravascular delivery. An emergency crash cart will remain available throughout the procedure

Group 2 will receive 10ml of 0.25% ropivacaine on each side

Eligibility Criteria

Age20 Years - 40 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Age range:20-40 years.
  • Both male and female individuals.
  • Patients classified as American Society of Anesthesiologists (ASA)I-II.
  • Patients scheduled for elective total thyroidectomy under general anesthesia

You may not qualify if:

  • Patient Refusal
  • Hypothyroidism,Hyperthyroidism,Retrosternal goiter
  • Premedication with preoperative analgesics
  • Excessive alcohol intake,Electrolyte imbalance
  • Pregnancy or lactation
  • Coagulation disorders
  • Additional surgical intervention

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dr Faisal Masood teaching Hospital Sargodha

Sargodha, Punjab Province, 40100, Pakistan

Location

MeSH Terms

Conditions

Pain, Postoperative

Interventions

Bupivacaine

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 15, 2026

First Posted

August 21, 2026

Study Start

January 22, 2026

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2026

Last Updated

August 21, 2026

Record last verified: 2026-08

Locations

PA(1)